Close Menu

NEW YORK (GenomeWeb) – Startup molecular diagnostic firm Prominex announced today it has raised $4 million in Series A1 financing. 

The funding comes from Casdin Capital and Paul Thomas, a cofounder and CEO of Prominex and former CEO of Roka Bioscience. 

Prominex will use the funding to further develop its technology — including a coupled hairpin amplification system, or CHASE, and waveguide detection — for highly multiplexed infectious disease assays, in partnership with point-of-care instrument developer Invetech.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.